These observations have led to the study of CREB involvement in HD [42, 43] and to the use of phosphodiesterase inhibitors, which prevent degradation of cyclic nucleotides, as potential therapeutical means [44, 45]. This evidence concerns the gene CREB1 and Huntington disease.